Asset
DECERNOTINIB
Vertex Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01590459 | phase2 | completed | 2012-04-01 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate |
| NCT01052194 | phase2 | completed | 2010-02-01 | 2011-07-01 | Vertex Pharmaceuticals Incorporated | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis |
| NCT01754935 | phase2 | completed | 2013-01-01 | 2014-01-01 | Vertex Pharmaceuticals Incorporated | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor |
| NCT01830985 | phase2_3 | completed | 2013-04-01 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis |
| NCT01886209 | phase1 | completed | 2013-06-01 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects |
FDA applications (0)
This company has no applications containing this asset.